They found that, while mGluR5 antagonists did not rescue mutant phenotypes in these FXS forebrain organoids, PI3K inhibitors rescued NPC proliferation defects and synaptic formation deficits, suggesting potential human-specific disease mechanisms that had not been seen in previous animal models and highlighting a potential therapeutic target for FXS in humans. The gene discussed is PIK3CB; the disease is fragile X syndrome.